EU and US could reach trade deal this weekend - Reuters
Investing.com -- Lonza Group (SIX:LONN) has released updated comparative financial results for 2024, reflecting its newly implemented “One Lonza” operating model, effective from April 1, 2025.
The new structure consists of three core CDMO platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The Capsules & Health Ingredients unit continues under its existing setup.
Under the updated framework, Lonza reported total 2024 net sales of CHF 6.57 billion, with core EBITDA of CHF 1.91 billion and a group margin of 29.0%.
Among the new platforms, Integrated Biologics delivered the strongest performance with CHF 2.88 billion in sales and a 36.2% EBITDA margin. Advanced Synthesis posted CHF 1.37 billion in revenue, and Specialized Modalities CHF 1.10 billion.
Capital expenditures totaled CHF 1.42 billion, with the largest share directed toward Integrated Biologics at CHF 607 million. Capsules & Health Ingredients generated CHF 1.05 billion in sales and CHF 256 million in core EBITDA.
For the first half of 2024, Lonza reported net sales of CHF 3.06 billion and core EBITDA of CHF 893 million, representing a margin of 29.2%. Again, Integrated Biologics led with CHF 1.34 billion in sales and a 35.5% margin.
These updated figures will serve as a baseline for Lonza’s half-year 2025 report, due on July 23.